Jonathan Adly

Founder and CEO TJM Labs

Last Reviewed: September 18, 2026

Executive Summary

Jonathan Adly is the founder and Chief Executive Officer of TJM Labs, which builds AI agents that perform the repetitive operational work of running a pharmacy: prescription intake, data entry, refills, prior-authorisation support and patient communication. He is a pharmacist who became an AI engineer, and the company is a direct response to something he watched for fifteen years, which is trained clinicians spending their days on data entry rather than on patients. What distinguishes TJM Labs from general-purpose healthcare automation is its Dual-Expert Model, under which every implementation pairs a pharmacist with an AI engineer, on the reasoning that pharmacy workflow is too idiosyncratic and too tightly regulated for engineers alone to automate safely. Founded in June 2024, the company reported in July 2026 that it had raised 100 million US dollars across three rounds in six months, was live in more than 450 pharmacies processing over 500,000 tasks a day, and had made two acquisitions.

Career Highlights

• Founded TJM Labs in June 2024 and leads it as Chief Executive Officer.
• Raised 100 million US dollars across three rounds within six months, ending with a 75 million US dollar Series B led by Elephant alongside Arthur Ventures and Updata Partners, announced on 2 July 2026.
• Scaled to more than 450 live pharmacies handling over 500,000 automated tasks daily.
• Acquired EncoreRx, extending data-entry automation, and Pharmesol, adding voice AI and patient communication.
• Developed the Dual-Expert Model, pairing a pharmacist with an AI engineer on every deployment so automation reflects real workflow, operational complexity and pharmacist oversight.
• Built the company’s first automation pilot in four days and later absorbed a tenfold volume increase from a partner with 95 percent of the work flowing through untouched.
• Grew the organisation to about 120 people, more than 50 of them pharmacists and engineers, working remote-first across six global regions.
• Serves independent, specialty, compounding and enterprise pharmacies in the United States and Canada.

Professional Journey

Adly spent roughly fifteen years working in pharmacy operations before he started a company. He holds a PharmD and an MBA, and during those years he repeatedly encountered the same structural waste: highly trained pharmacists occupied with prescription intake, faxes and data entry instead of clinical care. The problem was not that the work was hard but that it was mechanical, high-volume and unforgiving of error, which is precisely the combination that resists cheap fixes and invites automation. He taught himself to build, becoming an AI engineer as well as a pharmacist.

TJM Labs launched in June 2024, although the approach had been proven earlier: the team built a first automation pilot in four days, and when a partner’s volume increased tenfold the system absorbed 95 percent of it without intervention. That result established the core design principle. Adly’s conviction is that pharmacy automation fails when engineers build it alone, because pharmacy workflow carries regulatory constraints, exception handling and professional judgement that are invisible from outside. The Dual-Expert Model formalises this by putting a pharmacist and an AI engineer together on every implementation, with pharmacist oversight built into the resulting system rather than bolted on.

Growth has been fast and capital-intensive. Across six months the company raised a 10 million US dollar Series A, a 15 million US dollar Series A-1 and a 75 million US dollar Series B led by Elephant with participation from Arthur Ventures and Updata Partners, announced in July 2026 for a total of 100 million US dollars. Adly also used acquisitions to widen the product surface, buying EncoreRx to deepen data-entry automation and Pharmesol to add voice AI and patient communication, moving the company from back-office processing toward the patient-facing side of pharmacy operations.

The company now runs in more than 450 pharmacies, processing over 500,000 tasks each day, and serves independent, specialty, compounding and enterprise pharmacies in the United States and Canada. It employs roughly 120 people, more than 50 of them pharmacists and engineers, operating remote-first across six global regions while keeping teams embedded with customers. Adly’s framing of the company’s position is that pharmacy AI has stopped being a proposition and become infrastructure already running inside hundreds of pharmacies.

Education

Long Island University

Institution recorded from a prior research pass and not re-confirmed. TJM Labs states that Adly holds a Doctor of Pharmacy (PharmD) and a Master of Business Administration, but does not name the awarding institution for either degree, so neither is attributed here.